| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 1st January 2021 | Thomas J. Schall | 47,576 | Payment by withholding | $61.92 | $2,945,905.92 |
| 1st January 2021 | Susan M Kanaya | 10,000 | Exercise of derivative | $0.00 | |
| 1st January 2021 | Susan M Kanaya | 16,498 | Payment by withholding | $61.92 | $1,021,556.16 |
| 1st January 2021 | Thomas J. Schall | 30,000 | Exercise of derivative | $0.00 | |
| 1st January 2021 | Thomas J. Schall | 23,333 | Exercise of derivative | $0.00 | |
| 1st January 2021 | Susan M Kanaya | 10,000 | Exercise of derivative | $0.00 | |
| 1st January 2021 | Markus J. Cappel | 6,667 | Exercise of derivative | $0.00 | |
| 1st January 2021 | Markus J. Cappel | 6,667 | Exercise of derivative | $0.00 | |
| 1st January 2021 | Susan M Kanaya | 10,333 | Exercise of derivative | $0.00 | |
| 1st January 2021 | Thomas J. Schall | 34,566 | Exercise of derivative | $0.00 |
Chemo Centryx
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.
ChemoCentryx, Inc. focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.
Ticker: CCXI
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1340652
Employees: 82
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Revenue From Related Parties of $49 M for the period Apr 2020 to Jun 2020 in the context of all up
Revenue From Related Parties of $3 M for the period Apr 2020 to Jun 2020 in the context of Avacopan agreement
Revenue From Related Parties of $47 M for the period Apr 2020 to Jun 2020 in the context of Ccx140 agreement
Revenue From Related Parties of $55 M for the period Jan 2020 to Jun 2020 in the context of all up
Revenue From Related Parties of $7 M for the period Jan 2020 to Jun 2020 in the context of Avacopan agreement
Revenue From Related Parties of $48 M for the period Jan 2020 to Jun 2020 in the context of Ccx140 agreement
Revenue From Related Parties of $7 M for the period Apr 2019 to Jun 2019 in the context of all up
Revenue From Related Parties of $6 M for the period Apr 2019 to Jun 2019 in the context of Avacopan agreement
Revenue From Related Parties of $2 M for the period Apr 2019 to Jun 2019 in the context of Ccx140 agreement
Revenue From Related Parties of $16 M for the period Jan 2019 to Jun 2019 in the context of all up
Revenue From Related Parties of $12 M for the period Jan 2019 to Jun 2019 in the context of Avacopan agreement
Revenue From Related Parties of $3 M for the period Jan 2019 to Jun 2019 in the context of Ccx140 agreement
Fundamentals
Cash at Carrying Value: $333 M (0%)
Assets, Current: $507 M (190%)
Property, Plant and Equipment, Net: $6 M (158%)
Other Assets, Noncurrent: $1 M (-18%)
Assets: $542 M (159%)
Accounts Payable, Current: $3 M (122%)
Accrued Liabilities, Current: $19 M (0%)
Liabilities, Current: $56 M (-4%)
Long-term Debt, Excluding Current Maturities: $24 M (0%)
Other Liabilities, Noncurrent: $746 Th (34%)
Liabilities: $121 M (-15%)
Common Stock, Value, Issued: $69 Th (15%)
Common Stock, Shares, Issued: $69 M (14%)
Additional Paid in Capital, Common Stock: $852 M (71%)
Retained Earnings (Accumulated Deficit): $431 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $488 Th (53%)
Stockholders' Equity (Parent): $421 M (0%)
Liabilities and Equity: $542 M (159%)
Revenue: $49 M (-10%)
Research and Development: $19 M (-50%)
General and Administrative Expenses: $10 M (-46%)
Operating Income/Loss: $20 M (1073%)
Other Income, net: $119 Th (-62%)
EPS (basic): $0.32 (0%)
EPS (diluted): $0.29 (0%)
News
ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
14th January 2021
ChemoCentryx to Participate in Two Upcoming Investor Conferences
6th January 2021
ChemoCentryx to Present at Two Upcoming Investor Conferences
19th November 2020
ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
10th November 2020